Hemab

Copenhagen, Denmark Founded: 2019 • Age: 7 yrs
Preventative therapies for rare bleeding and thrombotic disorders are developed.
Request Access

About Hemab

Hemab is a company based in Copenhagen (Denmark) founded in 2019.. Hemab has raised $309.92 million across 4 funding rounds from investors including RA Capital, Deep Track Capital and Avoro Capital Advisors. The company has 10 employees as of December 31, 2022. Hemab offers products and services including HMB-001 and HMB-002. Hemab operates in a competitive market with competitors including Varmx, AbFero Pharmaceuticals, Alveron Pharma, TargED and Pangen Biotech, among others.

  • Headquarter Copenhagen, Denmark
  • Employees 10 as on 31 Dec, 2022
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
    $-22.15 M (USD)
    -345
    as on Dec 31, 2022
  • EBITDA
    $-22.84 M (USD)
    -302
    as on Dec 31, 2022
  • Total Equity Funding
    $309.92 M (USD)

    in 4 rounds

  • Latest Funding Round
    $157 M (USD), Series C

    Oct 27, 2025

  • Investors
    RA Capital

    & 9 more

  • Employee Count
    10

    as on Dec 31, 2022

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Hemab

Hemab offers a comprehensive portfolio of products and services, including HMB-001 and HMB-002. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Antibody that stabilizes factor VIIa for bleeding disorder treatment

Antibody for preventing bleeding in Von Willebrand Disease

People of Hemab
Headcount 10-50
Employee Profiles 27
Board Members and Advisors 10
Employee Profiles
People
Prafull Gandhi
Senior Director
People
Cécile Bonvoisin
SVP, CMC & Manufacturing
People
Shea Golden
Senior Clinical Research Associate
People
Kathryn Zwetchkenbaum
Manager, Human Resources & Executive Assistant

Unlock access to complete

Board Members and Advisors
people
John Maraganore
Chair
people
Linda Bain
Director
people
Uya Chuluunbaatar
Director
people
Christine Borowski
Observer

Unlock access to complete

Funding Insights of Hemab

Hemab has successfully raised a total of $309.92M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $157 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 4
  • Last Round Series C — $157.0M
  • First Round

    (20 Nov 2020)

  • Investors Count 10
Date Amount Transaction Name Valuation Lead Investors Investors
Oct, 2025 Amount Series C - Hemab Valuation Sofinnova Partners
Feb, 2023 Amount Series B - Hemab Valuation Access Industries
Jul, 2021 Amount Series A - Hemab Valuation Novo Holdings , Healthcap
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Hemab

Hemab has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include RA Capital, Deep Track Capital and Avoro Capital Advisors. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Deep Track Capital is engaged in biotechnology investment activities.
Founded Year Domain Location
Venture capital fund focused on biotechnology startups
Founded Year Domain Location
Private equity investments are directed toward ESG-focused companies.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Hemab

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Hemab

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Hemab Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Hemab

Hemab operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Varmx, AbFero Pharmaceuticals, Alveron Pharma, TargED and Pangen Biotech, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Therapeutic proteins are developed to restore blood clotting in patients.
domain founded_year HQ Location
Oral iron chelators are developed for iron overload disease treatment.
domain founded_year HQ Location
Drugs for haemorrhagic stroke and intracranial haemorrhage are developed.
domain founded_year HQ Location
Biological drugs for thrombosis treatment are developed by the company.
domain founded_year HQ Location
Developer of biosimilars and biologics
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Hemab

When was Hemab founded?

Hemab was founded in 2019 and raised its 1st funding round 1 year after it was founded.

Where is Hemab located?

Hemab is headquartered in Copenhagen, Denmark.

Is Hemab a funded company?

Hemab is a funded company, having raised a total of $309.92M across 4 funding rounds to date. The company's 1st funding round was a Series A of $14.96M, raised on Nov 20, 2020.

How many employees does Hemab have?

As of Dec 31, 2022, the latest employee count at Hemab is 10.

What does Hemab do?

Hemab was founded in 2019 in Copenhagen, Denmark, within the biotechnology sector. Novel antibody-based therapies are developed by the company to modulate the bodys clotting pathway, either by stabilizing or inhibiting clotting factors. These treatments target unmet needs in rare bleeding and thrombotic disorders, with a pipeline of candidates aimed at prophylactic options and potential functional cures. Operations focus on addressing life-threatening complications for affected patients.

Who are the top competitors of Hemab?

Hemab's top competitors include Varmx, Cadrenal Therapeutics and Alveron Pharma.

What products or services does Hemab offer?

Hemab offers HMB-001 and HMB-002.

Who are Hemab's investors?

Hemab has 10 investors. Key investors include RA Capital, Deep Track Capital, Avoro Capital Advisors, Maj Invest, and Rock Springs Capital.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available